Lantern Pharma's AI-Driven Approach to Fixing the Broken Biotech Model

What is the main topic of this announcement about Lantern Pharma?

The announcement covers Lantern Pharma’s alignment with industry leaders at the 2025 BioNTX iC3 Summit who declared the traditional biotech model ‘broken,’ and highlights how the company’s RADR AI platform can transform oncology drug development by making it more efficient and cost-effective.

Why is the traditional biotech model considered ‘broken’ according to this content?

The traditional model is considered broken because the process of making drugs is still largely manual, and the industry hasn’t adopted available technology fast enough to streamline discovery, accelerate clinical timelines, and reduce costs.

How does Lantern Pharma’s RADR platform address the broken biotech model?

Lantern’s RADR AI platform leverages over 200 billion oncology-focused data points and 200+ machine learning algorithms to streamline drug discovery, accelerate clinical timelines, and reduce costs, creating a more data-driven and efficient approach to drug development.

Who was involved in this industry discussion about fixing biotech?

Lantern Pharma’s CEO Panna Sharma served as both moderator and panelist at the 2025 BioNTX iC3 Summit, where biotech leaders collectively declared the traditional model broken and discussed AI-driven solutions.

When and where did this industry discussion take place?

The discussion occurred at the 2025 BioNTX iC3 Summit, which was covered in a Dallas Innovates article. Lantern Pharma is based in Dallas, Texas.

What are the potential benefits of adopting AI-driven platforms like RADR?

AI-driven platforms can streamline drug discovery, accelerate clinical timelines, reduce costs, and help create a more sustainable future for biotech by making the drug development process more efficient and data-driven.

What is Lantern Pharma’s current development pipeline status?

Lantern Pharma has a growing pipeline including a Phase 2 clinical program, multiple Phase 1 clinical trials, and an antibody-drug conjugate (ADC) program spanning multiple cancer indications with an estimated combined annual market potential of over $15 billion.

Where can readers find more information about Lantern Pharma?

Readers can view the full Dallas Innovates article at https://ibn.fm/DM9ur and access the latest news and updates in the company’s newsroom at https://ibn.fm/LTRN.